I disagree. Instead, this presentation was not used to pump the price but to:
1. Demonstrate they recognize the importance of SAP approval BEFORE data lock. Retail could care less about this, but regulators should care deeply that the process maintains integrity, unlike, for instance Optune.
2. Not pump the price, therefore continuing to make NWBO a better value for BP to acquire, whilst at the same time allowing LP to increase her ownership share through debt financing. Retail would have liked to see a presentation more along the lines of Dr. Liau’s two relatively recent talks, but instead we received an update on the information arm, and its vague comparison to the March 2017 data, which is a strange callback comparison. Clearly that “update” was not provided to help price per share.
On the other hand, the latter does seem to be a subtle foreshadowing that delayed phase iii results will likely outperform both the info arm and the March 2017 data. Only people following closely would pick up on this.
3. The two Direct trials are specifically geared toward rounding out the platform to include inoperable brain cancer. This is not going to help near or mid|term price per share, but BP needs to understand NWBO thinks it will ultimately be capable of additionally treating inoperable proneural tumors much more effectively with their platform.
4. Dr. Bosch essentially stated BP overemphasis on “neoantigens” is hype. This is not unlike BP’s prior “driver antigen” theories.
Dr. Prins also believes BP is missing the point that this is more about antigen quantity and variability matching rather than pretending like researchers really already know the one or two handfuls of antigens that might prevent tumor escape.
5. If BP is not already calling the shots behind the scenes, NWBO might be intentionally waiting for BMY to cough up their checkmate 548 interim results/recommendations in methylated GBM (which were due a month ago), so NWBO can demonstrate DCVax is the only game left in town to treat GBM. Otherwise, BMY could try to leverage and/or bluff their position that CIs are going to succeed in their current phase III methylated GBM trial, thus supposedly making DCVax-l less valuable. Personally, I think it’s time for BMY to show its hand in the 548 trial. They are late.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
